TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06305806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine Placebo
Description: The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine Placebo
Description: The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Care
Description: Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Care
Description: Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
Study: NCT06183580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofeedback training involving dACC
Description: Participants are pseudorandomized to the dACC group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the dACC. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase dACC neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofeedback training involving amygdala
Description: Participants are pseudorandomized to the rAMY group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the rAMY. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase rAMY neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed.
Study: NCT06406049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network intervention
Description: Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.
Study: NCT05579964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Study: NCT04553159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived stem cells
Description: Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived stem cells
Description: Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
Study: NCT05775887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UQSC2 Vaccine
Description: Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NVX-CoV2373 vaccine
Description: Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
Study: NCT06295276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teletherapy-guided exercise programme
Description: Exercise program guided by online sessions. Subjects perform this exercise program three times a week at home, so that they complete four sessions per week for six weeks. The duration of a session is approximately twenty minutes. There are six exercises with three sets and about fifteen repetitions. Subjects in the treatment group also receive an instructional video. The subjects keep a diary in which they record their adherence to the treatment protocol at home.~At the beginning of the intervention and after the sixth week, participants are assessed with ODI, NDI and SF36-Short and NRS-11 scales. At the end, we use the Global Rating Scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list/control intervention/delayed teletherapy intervention
Description: Subjects in the control group will be advised to maintain their daily routine but will be asked to refrain from other treatments to avoid co-interventions during the 6-week study period. However, the use of painkillers such as non-steroidal anti-inflammatory analgesics (NSAIDs) taken by study participants in all groups for more than 3 months is allowed and will be documented (taking a pragmatic approach). Any change in medication will be monitored and documented by the PT at each visit.
Study: NCT04952181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical biometry
Description: optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic biometry
Description: ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
Study: NCT05111782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach
Description: Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
Study: NCT04854161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Attunement to Affect Training
Description: Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathic Attunement to Affect Training
Description: Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Training
Description: Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focusing Oriented Therapy Training
Description: Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
Study: NCT05725239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
Study: NCT06099262

Intervention type: BEHAVIORAL
Intervention: GenPMTO
Description: GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
Study: NCT05186974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously
Study: NCT06211101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing training on kangaroo care guide
Description: Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
Study: NCT05186974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study: NCT06695910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monoglyceride Eicosapentaenoic acid (omega-3)
Description: 515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monoglyceride Eicosapentaenoic acid (omega-3)
Description: 515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: 698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.
Study: NCT04633187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
Study: NCT05728359

Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection

Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection

Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection

Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection
Study: NCT05108428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
Study: NCT05728359

Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection
Study: NCT05257109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
Study: NCT06124963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, 0.9 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks
Study: NCT05560685

Intervention type: OTHER
Group type: OTHER
Intervention: Outcomes4Me
Description: Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Team member participants will complete a semi-structured interview.
Study: NCT05287386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Study: NCT05659771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food properties manipulation to alter eating behavior and food and energy intake
Description: Food properties of commercially available food products